以IMAC预处理方案的自体外周血干细胞移植治疗急性髓细胞白血病的临床观察

 目的　应用IMAC预处理方案观察自体外周血干细胞移植（APBSCT）治疗急性髓细胞白血病（AML）的疗效。方法　用APBSCT治疗AML 14例。预处理方案：IMAC。结果　全部病例移植后造血重建，目前无病生存8例（57.1 %），平均生存时间26（8～72）个月，无移植相关性死亡。结论　IMAC预处理方案对AML是安全和有效的方案，预处理方案加入去甲氧柔红霉素有望提高总生存期。

Clinical investigation of idarubicin to intensify the MAC preparative regimens of autologous peripheral blood stem cell transplantation for patients with acute myeloid leukemia

Objective To investigate the effect of idarubiein to imensify the MAC (IMAC) as preparative regimen for autologous peripheral blood stem cell transplantation(APBSCT)in acute myeioid leukemia.Methods Fourteen patients with acute myeloid leukemia who underwent APBSCT were analysed. IMAC was used as preparative regimens.Results All patients were engrafted successfully.The disease-free survival could be Ben in 8 cases(57.1%),the median disease-free survival duration were 26(8-72)months and no treatment-related mortality was present.Conclusion This study suggested that addition of Idarubicin to the MAC preparative regimens Was safe,effective and feasible for patients with acute myeloid leukemia,and may improve disease-free survival and overall survival.